Shibi Likhite

4.8k citations

36 papers · 1.9k indexed · 1 hit paper · h-index 15

Impact in

Genetics top 1%
- Neurogenetic and Muscular Disorders Research
- Virus-based gene therapy research
Neurology top 1%
- Amyotrophic Lateral Sclerosis Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Parkinson's Disease Mechanisms and Treatments

Papers in

Genetics 22
- Neurogenetic and Muscular Disorders Research 21
- Virus-based gene therapy research 6
Neurology 11
- Amyotrophic Lateral Sclerosis Research 10

Co-authors: Kathrin Meyer Brian K. Kaspar Lyndsey Braun Laura Ferraiuolo Kevin D. Foust Carlos J. Miranda Arthur H.M. Burghes Jerry R. Mendell
Journals: Molecular Therapy (6 papers)Molecular Therapy — Methods & Clinical Development (5 papers)Neurology (3 papers)European Journal of Paediatric Neurology (2 papers)Neuromuscular Disorders (2 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Shibi Likhite

36 papers receiving 1.9k citations

Hit Papers

align trajectories log scale

Astrocytes from familial and sporadic ALS patients are toxic to motor neurons 2011 · 611 citations

Peers

Countries citing papers authored by Shibi Likhite

Since Specialization

Citations

This map shows the geographic impact of Shibi Likhite's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shibi Likhite with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shibi Likhite more than expected).

Fields of papers citing papers by Shibi Likhite

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shibi Likhite. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shibi Likhite. The network helps show where Shibi Likhite may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Shibi Likhite, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Shibi Likhite Line = papers co-authored together Shibi Likhite links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The postnatal injection of AAV9-FOXG1 rescues corpus callosum agenesis and other brain deficits in the mouse model of FOXG1 syndrome Molecular Therapy — Methods & Clinical Development ·C. C. B., Ali Basem, Shibi Likhite, Richard Uhlich, Teo Nam Kuan, Liwen Li, Kathrin Meyer, Jae W. Lee, Soo‐Kyung Lee	2024	4
2	Combination AAV therapy with galectin-1 and SOD1 downregulation demonstrates superior therapeutic effect in a severe ALS mouse model Molecular Therapy — Methods & Clinical Development ·Moparthy John Paul, Shibi Likhite, 占新佟, Onja Kim, H Chaparala, Wan-Ik Lee, Alan F Merry, L Chen, Wei-Chung Cheng, 刑法「改正」阻止実行委員会, Xiaojin Zhang, Kathrin Meyer	2024	2
3	Early postnatal administration of an AAV9 gene therapy is safe and efficacious in CLN3 disease Frontiers in Genetics ·Tyler B. Johnson, 喬夫森, Shibi Likhite, Dan Zhou, Katherine A. White, Jacob T. Cain, A. Eastwood, Derek Timm, Tho Huu-Hoang Nguyen, Frank Jackson, Ilah Muhafilah, A. Estella-Hermoso-de-Mendoza, Brian K. Kaspar, Kathrin Meyer, Jill M. Weimer	2023	9
4	In Vitro Modeling as a Tool for Testing Therapeutics for Spinal Muscular Atrophy and IGHMBP2-Related Disorders Biology ·李同伶, Shrestha Sinha-Ray, 刑法「改正」阻止実行委員会, Meysam Ganjibakhsh, Jung Yoon Choi, Samantha K. Powers, Xiaojin Zhang, Shibi Likhite, Kathrin Meyer	2023	6
5	Prevalence of Neutralizing Antibodies against Adeno-Associated Virus Serotypes 1, 2, and 9 in Non-Injected Latin American Patients with Heart Failure—ANVIAS Study International Journal of Molecular Sciences ·李同伶, Shibi Likhite, Paula K. Bautista‐Niño, Sergio Alejandro Gómez‐Ochoa, Luis Eduardo Echeverría, Jaime Jair Calapaqui Márquez, Y. Sue, Norma C. Serrano, Kathrin Meyer, Melvin Y. Rincón	2023	6
6	In-depth comparison of Anc80L65 and AAV9 retinal targeting and characterization of cross-reactivity to multiple AAV serotypes in humans Molecular Therapy — Methods & Clinical Development ·L Chen, Shibi Likhite, 占新佟, Moparthy John Paul, Vicki L. McGovern, 李同伶, Zihui Chi, Arthur H.M. Burghes, Kathrin Meyer	2023	5
7	AAV9-MCT8 Delivery at Juvenile Stage Ameliorates Neurological and Behavioral Deficits in a Mouse Model of MCT8-Deficiency Thyroid ·Xiao-Hui Liao, Pablo Avalos, 岩元真明, Paul Quataert, Judy Ullstrom Hogan, Catherine Bresee, Shibi Likhite, Jean‐Philippe Vit, Heike Heuer, Brian K. Kaspar, Kathrin Meyer, Alexandra M. Dumitrescu, Samuel Refetoff, Clive N. Svendsen, Gad D. Vatine	2022	15
8	Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV Cell Reports Methods ·Meisam Naeimi Kararoudi, Shibi Likhite, Александр Макухин, Kenta Yamamoto, M. Schwartz, Ojha Gunendra Prasad, محمد امین نریمانی, Ya Peng Wang, Aditya Soraganvi, 박차철, Gregory K. Behbehani, Nitin Chakravarti, Branden S. Moriarity, Kathrin Meyer, Dean A. Lee	2022	37
9	Sex-split analysis of pathology and motor-behavioral outcomes in a mouse model of CLN8-Batten disease reveals an increased disease burden and trajectory in female Cln8mnd mice Orphanet Journal of Rare Diseases ·Andrew D. Holmes, Katherine A. White, Dan Zhou, Tyler B. Johnson, Shibi Likhite, Kathrin Meyer, Jill M. Weimer	2022	4
10	Mechanisms of IRF2BPL-related disorders and identification of a potential therapeutic strategy Cell Reports ·Aakib Jawed Khan, Debdeep Dutta, 早稲田大学「世紀の日本」研究会, Samantha K. Powers, Muhammad Ajaz Hussian, Paweł Lisowski, Petar Glažar, Xiaojin Zhang, Pipasha Biswas, Onja Kim, Nikolaus Rajewsky, Marc Bickle, Nicolas Wein, Hugo J. Bellen, Shibi Likhite, Paul C. Marcogliese, Kathrin Meyer	2022	8
11	Intracranial delivery of AAV9 gene therapy partially prevents retinal degeneration and visual deficits in CLN6-Batten disease mice Molecular Therapy — Methods & Clinical Development ·Katherine A. White, Hemanth R. Nelvagal, 张厚忠, Bin Lü, Tyler B. Johnson, Tho Huu-Hoang Nguyen, Dan Zhou, 喬夫森, Elizabeth Braidwood, Shibi Likhite, Kathrin Meyer, Brian K. Kaspar, Jonathan D. Cooper, Shaomei Wang, Jill M. Weimer	2021	11
12	Onasemnogene abeparvovec-xioi: a gene replacement strategy for thetreatment of infants diagnosed with spinal muscular atrophy Drugs of today ·M. Schwartz, Shibi Likhite, Kathrin Meyer	2021	12
13	AAV9 Gene Therapy Increases Lifespan and Treats Pathological and Behavioral Abnormalities in a Mouse Model of CLN8-Batten Disease Molecular Therapy ·Tyler B. Johnson, Katherine A. White, 喬夫森, Jacob T. Cain, Ivan Ganev, Dan Zhou, A. Eastwood, Derek Timm, Tho Huu-Hoang Nguyen, Frank Jackson, Shibi Likhite, Kathrin Meyer, Jill M. Weimer	2020	30
14	Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-free, and Biomarker-Supported Strategy for fALS Molecular Therapy — Nucleic Acids ·Tommaso Iannitti, Jose Antonio Sanchez-Villacana, Shibi Likhite, Ian Coldicott, Katherine E. Lewis, Paul R. Heath, Adrian Higginbottom, Monika A. Myszczynska, Marta Milo, Guillaume M. Hautbergue, Kathrin Meyer, Brian K. Kaspar, Laura Ferraiuolo, Pamela J. Shaw, Mimoun Azzouz	2018	35
15	SMA THERAPIES I Neuromuscular Disorders ·Richard Shell, 森一恵, W. David Arnold, Shim Kang Bo, T. Prior, 誠司岩崎, Grace Paul, Linda Lowes, Lindsay N. Alfano, Katherine Berry, Eric M. DuBois, J. T. Kissel, Carlos Lourenco, Francis G. Ogrinc, Olha O. Dremliuha, Courtney Wells, Kathrin Meyer, Shibi Likhite, Maja Lumpe, Prasanth Yanambaka	2018	2
16	AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in SMA Type 1: Patients Treated Early with the Proposed Therapeutic Dose Were Able to Sit Unassisted at a Younger Age (S29.002) Neurology ·Lindsay N. Alfano, Linda Lowes, Samiah Al-Zaidy, Richard Shell, W. David Arnold, Louise R. Rodino‐Klapac, Thomas W. Prior, Katherine Berry, Kathleen Church, John T. Kissel, Sukumar Nagendran, James L’Italien, Douglas M. Sproule, Courtney Wells, Arthur H.M. Burghes, Kevin D. Foust, Kathrin Meyer, Shibi Likhite, Brian K. Kaspar, Jerry R. Mendell	2018	1
17	Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis Nature Medicine ·SungWon Song, Carlos J. Miranda, Lyndsey Braun, Kathrin Meyer, (unknown), Laura Ferraiuolo, Shibi Likhite, Adam K. Bevan, Kevin D. Foust, Michael J. McConnell, Christopher M. Walker, Brian K. Kaspar	2016	103
18	Delayed Disease Onset and Extended Survival in the SOD1^G93ARat Model of Amyotrophic Lateral Sclerosis after Suppression of Mutant SOD1 in the Motor Cortex Journal of Neuroscience ·Gretchen M. Thomsen, Genevíève Gowing, Magdalena Magdalena, Chris Kelly, Jean‐Philippe Vit, Sofia Borander, Pablo Avalos, Mor R. Alkaslasi, Laura Ferraiuolo, Shibi Likhite, Brian K. Kaspar, Clive N. Svendsen	2014	111
19	Therapeutic AAV9-mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS Molecular Therapy ·Kevin D. Foust, Desirée L. Salazar, Shibi Likhite, Laura Ferraiuolo, Dara Ditsworth, Hristelina Ilieva, Kathrin Meyer, Leah Schmelzer, Lyndsey Braun, Don W. Cleveland, Brian K. Kaspar	2013	160
20	Astrocytes from familial and sporadic ALS patients are toxic to motor neurons Nature Biotechnology ·Amanda Haidet-Phillips, Mark E. Hester, Carlos J. Miranda, Kathrin Meyer, Lyndsey Braun, (unknown), SungWon Song, Shibi Likhite, Matthew Murtha, Kevin D. Foust, Meghan Rao, А. Д. Тугов, Anja Kammesheidt, Ashley Christensen, Jerry R. Mendell, Arthur H.M. Burghes, Brian K. Kaspar Hit paper breakdown →	2011	611

About Shibi Likhite

Shibi Likhite is a scholar working on Genetics, Neurology, Molecular Biology, Genetics and Neurology, having authored 36 papers that have together received 1.9k indexed citations. Recurring topics across this work include Neurogenetic and Muscular Disorders Research (21 papers), Amyotrophic Lateral Sclerosis Research (10 papers), RNA modifications and cancer (7 papers), CRISPR and Genetic Engineering (7 papers), Virus-based gene therapy research (6 papers), RNA regulation and disease (4 papers), Lysosomal Storage Disorders Research (4 papers) and Pluripotent Stem Cells Research (3 papers). The work is most often cited by research in Genetics (778 citations), Neurology (1.0k citations), Neurology (364 citations), Developmental Neuroscience (157 citations) and Cellular and Molecular Neuroscience (306 citations). Shibi Likhite has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Kathrin Meyer, Brian K. Kaspar, Lyndsey Braun, Laura Ferraiuolo, Kevin D. Foust, Carlos J. Miranda, Arthur H.M. Burghes, Jerry R. Mendell, SungWon Song and Matthew Murtha. Their work appears in journals such as Molecular Therapy, Molecular Therapy — Methods & Clinical Development, Neurology, European Journal of Paediatric Neurology and Neuromuscular Disorders.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact